About Erica Shenoy, MD, PhD
Dr. Erica S. Shenoy is an Associate Physician at the Massachusetts General Hospital where she specializes in the evaluation and management of infections among both hospitalized and ambulatory patients. Dr. Shenoy sees patients in the Infectious Diseases clinic at the Mass General Main Campus, and is available for follow up, initial consultations and second opinions.
Dr. Shenoy is Associate Chief of the Infection Control Unit. She is an Associate Professor of Medicine at Harvard Medical School and is trained as a health economist. Her research has evaluated the clinical, operational and economic impact of competing infection control strategies for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) through clinical studies and mathematical modeling, has leveraged electronic health records for infection control surveillance, and applied machine-learning techniques to create risk prediction models for Clostridioides difficile infection. She has investigated and published on detection and prevention of nosocomial infections.
Dr. Shenoy is Medical Director of the Regional Emerging Special Pathogens Treatment Center at MGH, one of 10 facilities supported by the US Department of Health and Human Services as part of the regional treatment network for emerging pathogens. She has served as the Infectious Diseases and Infection Control advisor to MGH and MassGeneral Brigham for the COVID-19 response. She has published and lectured nationally and internationally on infection prevention and during the COVID-19 pandemic on approaches for SARS-CoV-2, the role of universal masking in healthcare settings and in the community, evaluation and management of healthcare workers infected with COVID-19, and on optimizing evaluation and isolation of patients with suspected and confirmed COVID-19 in healthcare settings.
Dr. Shenoy is a Fellow in both the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). She has served on the Guidelines Committee of SHEA and currently a member of SHEA’s Public Policy and Government Affairs Committee and co-chair of the Sterilization and High-Level Disinfection guidelines committee. An active member of IDSA, she previously served on the IDSA Antimicrobial Resistance Committee.
Clinical Interests:
- AIDS and HIV infection
- Hospital acquired infections
- Infectious diseases
- MRSA
- Multi-drug resistant infections
- Non Tuberculous Mycobacterial infections
- Prevention
- Tuberculosis (TB) including drug-resistant TB
- Vaccines and immunizations
- VRE
Treats:
- Adult
Languages:
- French, Spanish
Locations
Mass General Infectious Diseases
55 Fruit St.
Boston, MA 02114
Phone: 617-726-3906
Medical Education
- M.D.; Ph.D., Harvard Medical School
American Board Certifications
- Infectious Disease, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Centene/Celticare
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- Medicare ACO - ACD
- Medicare ACO - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
My research addresses the clinical, operational and economic impacts of competing Infection Control strategies for important nosocomial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). This involves hospital-based clinical studies, national survey-research, as well as “dry-bench” studies using computer-based simulation modeling. Our team collaborates with colleagues with expertise in computer science and articificial intelligence on risk prediction related to hospital acquired infections. I also collaborate with colleagues on research and implementation of antibiotic allergy evaluations.